Séverine Denoyelle

Séverine Denoyelle

Auto-generated profile, based on publicly available information

Séverine Denoyelle

Institut des Biomolécules Max Mousseron, UMR 5247 CNRS-Université Montpellier-ENSCM, Faculté de Pharmacie, 1919 route de Mende, Cedex 5, Montpellier 34293, France

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
CMCéline M’kadmi
Céline M’kadmi
ACAgustina Cabral
Agustina Cabral
FBFranco Barrile
Franco Barrile
JGJulien Giribaldi
Julien Giribaldi
SCSonia Cantel
Sonia Cantel
JFJean-alain Fehrentz
Jean-alain Fehrentz

10 August 2021 in Frontiers in Pharmacology
Verified
Journal Article
Open access
EMEmilio R. Mustafá
Emilio R. Mustafá
SGSantiago Cordisco González
Santiago Cordisco González
MDMarjorie Damian
Marjorie Damian
SCSonia Cantel
Sonia Cantel
SDSeverine Denoyelle
Severine Denoyelle
JRJesica Raingo
Jesica Raingo
The growth hormone secretagogue receptor (GHSR) signals in response to ghrelin, but also acts via ligand-independent mechanisms that include either constitutive activation or interaction with other G protein-coupled receptors, such as the dopamine 2 receptor (D2R). A key target of GHSR in neurons is voltage-gated calcium channels type 2.2 (CaV2.2). Recently, the liver-expressed antimicrobial peptide 2 (LEAP2) was recognized as a novel GHSR ligand, but the mechanism of action of LEAP2 on GHSR is not well understood. Here, we investigated the role of LEAP2 on the canonical and non-canonical modes of action of GHSR on CaV2.2 function. Using a heterologous expression system and patch-clamp recordings, we found that LEAP2 impairs the reduction of CaV2.2 currents induced by ghrelin-evoked and constitutive GHSR activities, acting as a GHSR antagonist and inverse agonist, respectively. We also found that LEAP2 prevents GHSR from modulating the effects of D2R signaling on CaV2.2 currents, and that the GHSR-binding N-terminal region LEAP2 underlies these effects. Using purified labeled receptors assembled into lipid nanodiscs and Forster Resonance Energy Transfer (FRET) assessments, we found that the N-terminal region of LEAP2 stabilizes an inactive conformation of GHSR that is dissociated from Gq protein and, consequently, reverses the effect of GHSR on D2R-dependent Gi activation. Thus, our results provide critical molecular insights into the mechanism mediating LEAP2 modulation of GHSR.

3 September 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
KSkhoubaib ben haj salah
khoubaib ben haj salah
MMMathieu Maingot
Mathieu Maingot
ABAnne-Laure Blayo
Anne-Laure Blayo
CMCéline M’kadmi
Céline M’kadmi
MDMarjorie Damian
Marjorie Damian
SDSéverine Denoyelle
Séverine Denoyelle

15 May 2018 in Organic Letters
Verified
Journal Article
Closed access
KSkhoubaib ben haj salah
khoubaib ben haj salah
BLBaptiste Legrand
Baptiste Legrand
MBMathieu Bibian
Mathieu Bibian
EWEmmanuel Wenger
Emmanuel Wenger
JFJean-Alain Fehrentz
Jean-Alain Fehrentz
SDSéverine Denoyelle
Séverine Denoyelle

13 November 2025 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
PMPaola Mantuano
Paola Mantuano
BBBrigida Boccanegra
Brigida Boccanegra
MMManuel Marinelli
Manuel Marinelli
ECEnrica Cristiano
Enrica Cristiano
RLRoberta Lenti
Roberta Lenti
ALAnnamaria De Luca
Annamaria De Luca
Growth hormone secretagogues (GHSs) are gaining interest as promising therapeutics for Duchenne muscular dystrophy (DMD) due to their broad activity profile and proven benefits in other muscle-wasting conditions. We previously found that JMV2894 - a pseudopeptide GHS - exerts functional, anti-inflammatory, and antifibrotic benefits in classic BL10-mdx mice, supported by in silico predictions of its interaction with ADAMTS-5 and matrix metalloproteinase 9 (MMP-9), both overactivated in DMD. This led us to test JMV2894 in the D2.B10-Dmdmdx/J (D2-mdx) mouse model, chosen for its hyper-fibrotic and atrophic disease phenotype. JMV2894 was administered subcutaneously at 640 or 1280 µg/kg for six weeks to 4-week-old D2-mdx mice, showing good tolerability. In vivo, the treatment partially improved hind limb plantar flexor torque, ultrasound volume, and reduced gastrocnemius (GC) muscle echodensity. While decreasing the expression of matrix-remodeling genes (i.e., MMP-9, ADAMTS-5, transforming growth factor beta-1, type I collagen α1), JMV2894 only mildly alleviated GC muscle fibrosis histologically. However, JMV2894 - particularly at the lower dose - exerted a remarkable anti-atrophic action, evidenced by increased GC myofiber size and decreased gene expression of Atrogin and Muscle RING Finger 1. Enhanced insulin-like growth factor 1 (IGF-1) transcript and plasma levels, along with increased IGF-1 receptor and downstream signalling proteins, suggest that JMV2894 actions are most likely GH-mediated. These effects occurred despite limited muscle drug exposure, highlighting the need for improved formulations to enhance bioavailability. Overall, our results show that GHSs exert different actions in dystrophic settings, likely related to distinct disease phenotype, reflecting the complexity of translational exercise towards universal therapies in DMD.